wla(warner lambert) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zoltan! who wrote (129)	12/2/1997 12:57:00 AM
From: John Powell	Read Replies (1) of 942

From the same article you cite: >>> The company said it had expected the number of reports of increased liver enzymes to rise following its Oct. 31 warning as doctors and patients became aware of the side effect. Even though the reporting of side effects has accelerated in the past month, the incidence of liver problems is still MUCH LOWER than the 2% rate seen during the drug's clinical trials, the company spokesman said. <<< The newly reported cases of liver problems are still way below what was observed in the clinical trials. This is a tremendous over-reaction on WLA. I am long on WLA and think that the market will very quickly realize their mistake on this stock. LFT monitoring is not that expensive when you consider the cost of daily therapy. The new FDA recommendations are for: LFT at start of therapy, once/month for first six months, every other month for next six months, and periodically thereafter. The FDA also stated "... at present the agency continues to find the benefits outweigh the risks for treating appropriately selected and monitored type 2 diabetes patients with Rezulin."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next